Key result
Rosuvastatin 20 mg/day significantly increased the number of acceptable blood pressure and systemic perfusion days compared to placebo (11 vs. 8 days; p=0.0001) in septic ICU patients.
Why the study?
Does rosuvastatin 20 mg/day improve acceptable blood pressure and systemic perfusion days in septic ICU patients?
RCT (n=108)
Double-blind
parallel
Does rosuvastatin 20 mg/day improve acceptable blood pressure and systemic perfusion days in septic ICU patients?
Absolute Event Rate: 11% vs 8%
p-value: p=0.0001
Rosuvastatin 20 mg/day improved hemodynamic stability and reduced vasopressor requirements in septic ICU patients without significant muscle or liver toxicity.
Supports adjunctive rosuvastatin for hemodynamic stability in septic shock; extends statin pleiotropy evidence with RCT data.
BackgroundStatins anti-inflammatory and antioxidant properties improve vascular function in septic patients. The aim of this prospective study was to assess vasopressor effect and safety of rosuvastatin therapy in septic patient.MethodsOne hundred and eight patients admitted to intensive care unit (ICU) with suspected or confirmed infection plus at least 2 systemic inflammatory response syndrome criteria were included in this prospective double-blinded randomized two groups’ parallel study. Group R received standard therapy and rosuvastatin 20 mg/day and Group C received standard therapy with placebo/day for 14 days.The primary endpoint was number of acceptable blood pressure and systemic perfusion days (ABPSPD). Secondary outcome included time to initial ABPSPD, vasopressor dose and duration, arterial lactate, organ dysfunction or failure free days, ICU and hospital stay, 28 ICU and hospital mortality, CPK and transaminases level.ResultsThe number of ABPSPD was significantly increased 11(3) vs. 8 (3) (p = 0.0001), with a shorter time to initial ABPSPD 18(21) vs. 41(37) h (p = 0.0001) in Group R than Group C. Norepinephrine dose 0.8 (0.5) vs. 1.6 (0.6) and duration 3(2) vs. 6(3) were significantly reduced in Group R with no significant elevation in transaminases or CPK.ConclusionsRosuvastatin 20 mg/day in septic patients increased number ABPSPD, decreased time to initial ABPSPD, norepinephrine dose and duration, with no significant elevation in transaminases or CPK.
No takes yet. Share an insight, caveat, or question.
Gendy et al. (2014) conducted an RCT in Sepsis (n=108). Rosuvastatin vs. Placebo was evaluated on Number of acceptable blood pressure and systemic perfusion days (ABPSPD) (p=0.0001). Rosuvastatin 20 mg/day significantly increased the number of acceptable blood pressure and systemic perfusion days compared to placebo (11 vs. 8 days; p=0.0001) in septic ICU patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: